News Test could end uncertainty in inherited muscle diseases A new study suggests long-read 'nanopore' sequencing could transform the diagnosis of inherited diseases and unlock new insights for drug discovery.
Oncology From promise to practice: What must happen next for genetic ... The systems needed to deliver GBT testing consistently across the NHS are still evolving to keep pace with these scientific advances.
News 23andMe study explains variable results with obesity drugs Gene variants could explain why some people lose more weight than others with GLP-1 drugs, and why some are more prone to side effects.
Patients Sponsored Why rare kidney diseases must be part of the CKD conversatio... A look at the benefits of genetic testing in diagnosis of rare kidney diseases, from HealthLumen.
News 23andMe fined £2.31m over UK users' genetic data breach Genetic testing company 23andMe is facing a hefty fine from the UK's data protection watchdog for failing to protect its customers' data.
News Former CEO wins bidding war for 23andMe, beating Regeneron 23andMe's co-founder and former chief executive, Anne Wojcicki, looks set to regain control of the genetic testing business.
News Iambic prices its IPO, seeking to raise up to $160m AI-powered drug discovery company Iambic Therapeutics has announced the terms of its Nasdaq IPO, pitching at a valuation of more than $800m.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.